Discussion {#onco12194-sec-0005}
==========

The intensity of acute OXA‐induced neuropathic phenomena may significantly increase the odds of developing chronic long‐term neuropathy. The association between intense acute sensory symptoms and greater risk of developing chronic pain has been described in other settings and is probably related to the development of central neuronal plastic changes such as central sensitization after acute injury. Thus, it has been hypothesized that the modulation of neuronal firing related to acute pain by the use of pregabalin would decrease the likelihood of the development of neuropathic pain.

![Consolidated Standards of Reporting Trials flowchart of screened and included patients.](onco12194-fig-0001){#onco12194-fig-0001}

Based on this rationale, we tested the hypothesis that the preemptive use of pregabalin a few days before and after OXA would have a preventive effect on chronic OXAIPN and its most troublesome symptom: neuropathic pain. However, we found no effects of pregabalin in this scenario. It failed to impact both the acute and chronic pains seen after OXA. Pain‐related effects, interference, and QoL were not influenced by the active treatment.

Trial Information {#onco12194-sec-1101}
=================

**Disease**CRC**Stage of Disease/Treatment**Prevention**Prior Therapy**None**Type of study ‐ 1**Phase III**Type of study ‐ 2**Randomized**Primary Endpoint**Pain intensity**Secondary Endpoint**Safety**Secondary Endpoint**QoL**Secondary Endpoint**Cummulative mFLOX dose**Secondary Endpoint**NPSI score**Secondary Endpoint**Presence of neuropathic pain**Secondary Endpoint**CTC‐neuropathy**Additional Details of Endpoints or Study Design** Pain characterization: Pain intensity and interference with daily activities were assessed by the short-form of the Brief Pain Inventory (BPI), which evaluates current pain intensity as well as the worst, least, and average (study\'s main outcome) pain intensity (11‐point scale) in the previous 24 hours. The BPI also assesses pain interference with daily activities (general activities, mood, walking, work, relationships with others, sleep, and enjoyment of life) in an 11‐point scale from 0 (no pain/no interference) to 10 (as severe as possible) \[[28](#onco12194-bib-0028){ref-type="ref"}\]. The McGill Pain Questionnaire (MPQ)-short form assesses different dimensions of pain (sensory, affective, and evaluative) \[[29](#onco12194-bib-0029){ref-type="ref"}\], \[[30](#onco12194-bib-0030){ref-type="ref"}\]. Assessments took place 1 week after each OXA infusion at planned visits and during the follow-up period by research nurses not implicated in OXA administration. The presence of neuropathic pain characteristics was assessed by the Douleur Neuropathique-4 (0--10, positive ≥4) \[[31](#onco12194-bib-0031){ref-type="ref"}\]. Neuropathic Pain Symptom Inventory (0--100) was used for neuropathic pain profiling \[[32](#onco12194-bib-0032){ref-type="ref"}\], \[[33](#onco12194-bib-0033){ref-type="ref"}\]. Oxaliplatin-Related Neuropathy: The presence of neuropathy was assessed by the reduced version of the total neuropathy score (rTNS) \[[34](#onco12194-bib-0034){ref-type="ref"}\] at baseline and at the last visit by blinded neurophysiologists with no other role in the study. The severity of oxaliplatin-induced neuropathy was assessed by the NCI-CTCv3 \[[34](#onco12194-bib-0034){ref-type="ref"}\], \[[35](#onco12194-bib-0035){ref-type="ref"}\], \[[36](#onco12194-bib-0036){ref-type="ref"}\]. Concomitant Analgesic Medication Use: The number of psychotropic analgesics used during the trial was quantified in each visit by the BPI. The use of alpha-2-delta (pregabalin and gabapentin) ligands outside the protocol was not allowed during the study. Quality of Life and Patient Report Outcomes: The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core (EORTC‐QLQ‐C30v3)‐items 29/30 were used to evaluate general health and quality of life (QoL). Depression and anxiety were assessed by the Hospital Anxiety and Depression Scale (HADS) \[[37](#onco12194-bib-0037){ref-type="ref"}\], which provides anxiety (0--21) and depression (0--21) scores. Safety: Safety was assessed by the presence and severity of adverse effects (AEs), discontinuation and death. CTCAE term (AE description) and grades were recorded according to the NCI‐CTCAE‐v3.0 \[[35](#onco12194-bib-0035){ref-type="ref"}\]. Statistical Methods: Descriptive data analysis presented categorical variables as observed counts, and continuous variables as mean/median with the corresponding standard errors/range. The exploratory analysis evaluated distributions, frequencies, and percentages for each of the numeric and categorical variables. Categorical variables were evaluated for near-zero variation \[[38](#onco12194-bib-0038){ref-type="ref"}\]. Extensive graphical displays were used for both univariate analysis and bivariate associations, accompanied by tests such as the maximal information coefficient \[[39](#onco12194-bib-0039){ref-type="ref"}\] and non-negative matrix factorization algorithms \[[18](#onco12194-bib-0018){ref-type="ref"}\] for numeric variables. Missing data were explored using a combination of graphical displays involving univariate, bivariate, and multivariate methods. Imputation was performed using a k-nearest neighbor\'s algorithm (*n* = 5) \[[40](#onco12194-bib-0040){ref-type="ref"}\]. Balance at baseline was evaluated through one-way analysis of variance and chi-square tests. These tests were conducted with both the originally randomized sample as well as with those meeting the criteria for inclusion in the final analysis, based on time in the study and minimum time providing outcomes data. After balance evaluation, the modeling strategy employed a series of generalized estimating equation models to evaluate the association between all previously reported outcomes and the intervention versus placebo, accounting for all intermediate follow-up measurements. Of importance, confounding adjustment was applied to our analyses to account for bias resulting from imbalances generated through dropout rates and exclusion criteria. Results were reported as predicted means for numeric outcomes (significance was present when 95% CI values from each variable did not intersect between groups) and odds ratios for Boolean (yes/no) outcomes with 95% CI. Per protocol, our main results concerned participants who provided outcome data beyond visit eight (i.e., patients who receive at least 2 months of chemotherapy and were followed for at least 3 months, thus staying in the protocol for at least 5 months). However, the analyses also followed an intention‐to‐treat protocol by performing a sensitivity analysis where all subjects were included regardless of their follow‐up time or therapy. A single post‐hoc analysis was reported as per our protocol, stratifying outcomes by the presence of metastasis at baseline. All analyses were performed using the R‐statistical language. A sample of 154 patients randomly assigned to the treatment or placebo group (77 for each arm) was required for 90% power and type‐I error = 0.05. Taking into account the prevalence of acute OXAIPN and 30% losses due to deaths/dropouts during the follow‐up, we estimated 100 participants per group would be appropriate. **Investigator\'s Analysis**Level of activity did not meet planned endpoint

Drug Information for Phase III Pregabalin {#onco12194-sec-1281}
=========================================

**Drug 1** **Generic/Working name**Pregabalin**Trade name**Lyrica**Company name**Pfizer**Drug type**Other**Drug class**Other**Dose**150--600 mg p.o. q.d. milligrams (mg) per flat dose**Route**Oral (p.o.)**Schedule of administration** This was a double-blind, placebo-controlled randomized trial. Patients referred to our institution\'s outpatient clinic were screened for participation and were randomized in blocks of twenty to receive either placebo or pregabalin (1:1). Oral medication (pregabalin or placebo) was taken in an outpatient setting intermittently in flexible daily doses of 150--600 mg in a time period extending from 3 days before to 3 days after each OXA infusion (i.e., weeks 1‐3‐5 in each of the three cycles). During the 4 days preceding the very first infusion of OXA in the study, the dose of pregabalin or placebo was progressively titrated from 75 mg b.i.d. up to 300 mg b.i.d. Titration was monitored by programmed phone calls from study nurses blinded to the treatment arm, who coached patients to take medications and adjust the daily dose of medication according to each individual\'s tolerance and side effects profile, according to a standardized protocol. Thus, patients had medication titrated up to their highest tolerable dosage before the first Oxa infusion (150 mg increase/day), and from this point onward, this individualized dosage was used in a fixed-dose regimen (starting at the top dose from beginning) 3 days before and 3 days after each of the following Oxa infusions throughout the study. Patients were considered noncompliant to the protocol when presenting more than three absences in protocol visits or in case of failure to take more than 50% of the expected study medication dose before more than two treatment infusions of OXA. Compliance was assessed by counting empty blisters. Allocation concealment was assured by the use of opaque envelopes labeled with a code designating the study protocol number of each participant and the study group. 

Drug Information for Phase III Placebo {#onco12194-sec-1201}
======================================

**Drug 1** **Generic/Working name**Placebo**Trade name**Placebo**Drug type**Other**Drug class**Other**Dose**150--600 milligrams (mg) per flat dose**Route**Oral (p.o.)**Schedule of administration** (a) Chemo regimen: patients were scheduled to receive modified‐FLOX (5‐FU bolus 500 mg/m^2^ + bolus of leucovorin 200 mg/m^2^/week for 6 weeks + OXA 85 mg/m^2^ in 2 hour‐infusions at weeks 1--3‐5 every 8 weeks) (b) Intervention: pregabalin: daily, 3 days before and 3 days after OXA infusion; placebo provided in a blister pack identical to that for the pregabalin in the same dose regimen **Drug 2** **Generic/Working name**Placebo**Trade name**Placebo**Company name** **Drug type**Other**Drug class**Other**Dose**150 milligrams (mg) per flat dose**Route**Oral (p.o.)**Schedule of administration**Similar to pregabalin

Patient Characteristics for Phase III Pregabalin {#onco12194-sec-1401}
================================================

**Number of patients, male**99**Number of patients, female**100**Stage** Eligible patients were chemotherapy‐naïve adults with histologically confirmed CRC (stage III/IV) with a Karnofsky Performance Status ≥50, scheduled to receive at least one complete cycle (e.g., three oxapliplatin infusions) of modified‐FLOX. Exclusion criteria were known central nervous system (CNS) metastasis, uncontrolled concurrent systemic illness, symptoms of peripheral neuropathy (NCI‐CTCAE‐v3.0‐grade ≥1), presence of possible neuropathic pain (Douleur Neuropathique questionnaire ≥4), or positive plasma ß‐hCG. The protocol was approved by our institution\'s Ethics Review Board (007/11) and registered as NCT0145016. All patients gave written informed consent to participate in the study protocol. Of 199 subjects undergoing randomization, 143 were included in analyses (Fig. [1](#onco12194-fig-0001){ref-type="fig"}). Additional information on the balance between arms for the entire patient sample is available in supplemental online Table [1](#onco12194-tbl-0001){ref-type="table"}. 90.5% of patients in the pregabalin arm and 91.3% of patients in the placebo arm received at least three complete cycles of modified‐FLOX (9‐OXA infusions). Fifty‐six patients were not included in the analyses (pregabalin group: one died before chemo, 20 received less than one chemo cycle and had follow‐up for less than 3 months, two discontinued chemo; placebo group: two died before chemo started, 25 received less than one chemo cycle and had follow‐up for less than 3 months, six discontinued chemo). **Age**Median (range): 57.13 ± 10.51**Number of prior systemic therapies**Median (range): none**Cancer types or histologic subtypes**CRC: 199

Primary Assessment Method for Phase III Pregabalin {#onco12194-sec-1233}
==================================================

Assessment Number of patients screened402Number of patients enrolled199Number of patients evaluable for toxicity199Number of patients evaluated for efficacy143Evaluation methodClinical (questionnaire and scales)(Median) duration assessments response duration12 months(Median) duration assessments duration of treatment6 months

Adverse Events: Phase III Pregabalin {#onco12194-sec-6235}
====================================

imageJohn Wiley & Sons, Ltd.[^1][^2][^3]

Assessment, Analysis, and Discussion {#onco12194-sec-1501}
====================================

CompletionStudy completedPharmacokinetics/PharmacodynamicsNot collectedInvestigator\'s AssessmentLevel of activity did not meet planned endpoint

 {#onco12194-sec-0006}

The intensity of acute OXA‐induced neuropathic phenomena may significantly increase the odds of developing chronic long‐term neuropathy \[[1](#onco12194-bib-0001){ref-type="ref"}\], \[[2](#onco12194-bib-0002){ref-type="ref"}\]. The association between intense acute sensory symptoms and greater risk of developing chronic pain has been described in other settings \[[3](#onco12194-bib-0003){ref-type="ref"}\], \[[4](#onco12194-bib-0004){ref-type="ref"}\] and is probably related to the development of central neuronal plastic changes such as central sensitization after acute injury. Central sensitization occurs in central relay centers, such as the spinal cord, and comprises a series of neuronal processes leading to sensory gain in the nervous system \[[5](#onco12194-bib-0005){ref-type="ref"}\]. In fact, it has been shown that OXA triggers activation of glutamate‐NMDA receptors in the spinal cord, a major step in central sensitization to painful stimuli \[[6](#onco12194-bib-0006){ref-type="ref"}\]. Thus, it has been hypothesized that the modulation of the neuronal firing related to acute pain by the use of pregabalin would decrease the likelihood of the development of neuropathic pain. This strategy has been tested in several models of postoperative pain, in which gabapentinoids were administered perioperatively with the aim of decreasing the incidence of long‐term chronic pain, yielding promising results \[[7](#onco12194-bib-0007){ref-type="ref"}\]. Also, it has been shown that a single 300‐mg dose of oral pregabalin was sufficient to reach significant concentrations in the cerebral spinal fluid \[[8](#onco12194-bib-0008){ref-type="ref"}\], and the use of gabapentinoids before and a few days after surgery not only significantly decreased perioperative pain \[[9](#onco12194-bib-0009){ref-type="ref"}\] but also seemed to reduce chronic post‐surgical pain.

Based on this rationale, we tested the hypothesis that the preemptive use of pregabalin a few days before and after OXA would have a preventive effect on chronic OXAIPN and its most troublesome symptom: neuropathic pain. However, we found no effects of pregabalin in this scenario. It failed to impact both the acute and chronic pains seen after OXA. Pain‐related effects, interference, and quality of life were not influenced by the active treatment.

Previous studies have tried to prevent \[[10](#onco12194-bib-0010){ref-type="ref"}\], \[[11](#onco12194-bib-0011){ref-type="ref"}\] or treat \[[12](#onco12194-bib-0012){ref-type="ref"}\] OXA‐induced neuropathy with limited or no success. While some studies have tested a prophylactic approach to OXA‐induced neuropathy by administering drugs before chemotherapy was started \[[10](#onco12194-bib-0010){ref-type="ref"}\], \[[11](#onco12194-bib-0011){ref-type="ref"}\], \[[13](#onco12194-bib-0013){ref-type="ref"}\], \[[14](#onco12194-bib-0014){ref-type="ref"}\], \[[15](#onco12194-bib-0015){ref-type="ref"}\], others have focused on patients already with OXAIPN \[[12](#onco12194-bib-0012){ref-type="ref"}\], \[[16](#onco12194-bib-0016){ref-type="ref"}\], \[[17](#onco12194-bib-0017){ref-type="ref"}\] and already presenting with neuropathic symptoms \[[18](#onco12194-bib-0018){ref-type="ref"}\], thus performing a formal treatment trial rather than a preemptive or prophylactic approach. The bulk of evidence is negative for both scenarios \[[12](#onco12194-bib-0012){ref-type="ref"}\], \[[14](#onco12194-bib-0014){ref-type="ref"}\], \[[19](#onco12194-bib-0019){ref-type="ref"}\], \[[20](#onco12194-bib-0020){ref-type="ref"}\], with rare exceptions \[[17](#onco12194-bib-0017){ref-type="ref"}\], \[[21](#onco12194-bib-0021){ref-type="ref"}\]. Importantly, the large majority of studies have not used validated pain measurement tools \[[10](#onco12194-bib-0010){ref-type="ref"}\], \[[11](#onco12194-bib-0011){ref-type="ref"}\], \[[13](#onco12194-bib-0013){ref-type="ref"}\], \[[14](#onco12194-bib-0014){ref-type="ref"}\], \[[16](#onco12194-bib-0016){ref-type="ref"}\], \[[19](#onco12194-bib-0019){ref-type="ref"}\], \[[22](#onco12194-bib-0022){ref-type="ref"}\], \[[23](#onco12194-bib-0023){ref-type="ref"}\], while most have used the common terminology criteria (CTC) adverse events grading system as the primary outcome measurement. While this choice is sound and supported by robust evidence \[[24](#onco12194-bib-0024){ref-type="ref"}\], it must be kept in mind that most patients with OXAIPN have small‐fiber‐predominant polyneuropathy \[[1](#onco12194-bib-0001){ref-type="ref"}\], which has as its main symptom neuropathic pain. However, pain itself (i.e., visual analog scale (VAS), BPI) or neuropathic pain symptoms (i.e., NPSI) have rarely been used as a primary outcome in studies on OXAIPN, and only a few have used validated pain scales or questionnaires at all \[[12](#onco12194-bib-0012){ref-type="ref"}\], \[[20](#onco12194-bib-0020){ref-type="ref"}\], \[[21](#onco12194-bib-0021){ref-type="ref"}\], \[[25](#onco12194-bib-0025){ref-type="ref"}\]. Also, neuropathic symptoms have only rarely been evaluated \[[17](#onco12194-bib-0017){ref-type="ref"}\], \[[26](#onco12194-bib-0026){ref-type="ref"}\]. In fact, "pain" is not mentioned in the CTC grading system for "neuropathy", which is centered on the functional impairment due to paresthesia. It is also noteworthy that no larger trial published so far used formal neuropathic pain criteria or grading system \[[27](#onco12194-bib-0027){ref-type="ref"}\] among its endpoints, or one of the many published screening tools for neuropathic pain.

Even though the results of our study are in line with the previous literature, the study has limitations. For instance, the incidence of chronic neuropathic pain was only mild in our sample, maybe due to the inclusion of patients with metastatic disease, who may receive fewer cycles of Oxa. The current management of acute OXA‐induced dysesthesias by reduction of OXA dosage in subsequent chemotherapy sessions may have also played a role in the reduction of chronic OXAINP in our sample. Also, the placebo group receive significantly more medication than the pregabalin arm. However, the net difference between groups was equivalent to approximately one pill of medication (75 mg). Because the average participant took 5 to 6 pills daily and all participants were pregabalin‐nû£ve, we believe this may not have played a major role in our results.

In conclusion, the use of pregabalin failed to decrease acute or chronic OXA‐related pain despite being safe and relatively well tolerated.

Figures and Tables {#onco12194-sec-1005}
==================

![Effects of study medications on pain intensity. **(A)**: Brief Pain Inventory pain intensity scores (0--10). **(B)**: Neuropathic pain symptoms (Douleur Neuropatique‐4). Statistical significance is considered when confidence intervals from both groups do not intersect.\
\*Main outcome.\
Abbreviations: BPI, brief pain inventory; DN‐4, Douleur Neuropatique‐4.](onco12194-fig-0002){#onco12194-fig-0002}

###### Baseline characteristics in both study groups

![](onco12194-tbl-0002){#nlm-graphic-11}

For all these scores/questionnaires (VAS, HADS, rTNS), higher values indicate more pain/more intense mood symptoms/more signs of neuropathy.

The values are presented as mean ± SD or *n*. Statistical significance was set at *p* \< .05.

Abbreviations: HADS, hospital anxiety and depression scale; rTNS, total neuropathy score‐reduced; SD, standard deviation; VAS, visual analog scale.

###### Study outcomes taking into account all measurements over the entire trial period

![](onco12194-tbl-0003){#nlm-graphic-13}

The values were presented as predicted means from generalized estimating equations (95% CI). Statistical significance is considered when CI from both groups do not intersect.

For all these scores/questionnaires (BPI, DN4, HADS, rTNS), higher values indicate more pain/more intense mood symptoms/more signs of neuropathy.

Main outcome.

Abbreviations: BPI, brief pain inventory; CI, confidence interval; DN‐4, Douleur Neuropathique‐4; HADS, hospital anxiety and depression scale; NPSI, neuropathic pain symptom inventory; rTNS, total neuropathy score‐reduced.

###### Pain outcomes comparison between interventions considering the dichotomous variables

![](onco12194-tbl-0004){#nlm-graphic-15}

For all these scores/questionnaires, higher values indicate more severe symptoms.

Abbreviations: CI, confidence interval; CTC, common toxicity criteria; DN‐4, Douleur Neuropathique‐4; VAS, visual analog scale.
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[^1]: Abbreviations: NC/NA, no change from baseline/no adverse event.

[^2]: Safety was assessed by the presence and severity of AEs, discontinuation, and death. CTCAE term (AE description) and grades were recorded according to the NCI‐CTCAE‐v3.0.(17)

[^3]: At the last visit, AEs were present in 31% (CTC‐grade 1 = 54%) of patients in the pregabalin arm and in 33% of patients (CTC‐grade 1 = 50%) in the placebo arm. Twenty‐six patients died in the pregabalin arm and 25 patients died in the placebo arm during the study, none related to the trial.
